ICER to assess unsupported price increases on prescription drugs in US market in 2020 Media release 01 May 2021 Pages: 1 - 1
Economic costs of opioid-use disorder and fatal opioid overdose substantial in the US 2017 Clinical study 01 May 2021 Pages: 2 - 2
Financial hardship in survivors of adolescent and young adult cancer Clinical study 01 May 2021 Pages: 3 - 3
Financial-burden assessment in cancer: lack of measures for adolescents and young adults Non-clinical study 01 May 2021 Pages: 4 - 4
Forecasting costs of drug treatment for childhood cancer in LMICs Clinical study 01 May 2021 Pages: 5 - 5
Impact of increasing investment in key HIV populations in Nigeria Clinical study 01 May 2021 Pages: 7 - 7
Imrecoxib "valuable treatment option" for patients with osteoarthritis in China Clinical study 01 May 2021 Pages: 9 - 9
Inflammatory bowel disease substantial burden among children in Manitoba, Canada Clinical study 01 May 2021 Pages: 10 - 10
Intravitreal bevacizumab cost saving for macular oedema in the UK Non-clinical study 01 May 2021 Pages: 11 - 11
Levetiracetam for newly diagnosed generalised or unclassified epilepsy: fewer QALYs, higher costs than valproate Clinical study 01 May 2021 Pages: 12 - 12
Metastatic renal-cell carcinoma treated with first-line monotherapy: considerable burden, high unmet needs Clinical study 01 May 2021 Pages: 13 - 13
Multitarget stool DNA test cost effective for CRC screening in Alaska Clinical study 01 May 2021 Pages: 14 - 14
Pembrolizumab cost effective as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma Clinical study 01 May 2021 Pages: 15 - 15
Pembrolizumab in dMMR/MSI-H unresectable or metastatic endometrial cancer: substantial gain in life-years at acceptable cost in the US Clinical study 01 May 2021 Pages: 16 - 16
Sentinel lymph node mapping "attractive potential alternative" for nodal assessment in atypical endometrial hyperplasia Clinical study 01 May 2021 Pages: 19 - 19
Specialty and cancer drugs set to drive US drug expenditure in 2021 Clinical study 01 May 2021 Pages: 20 - 20
Sugammadex budget saving for reversal of neuromuscular blockade Clinical study 01 May 2021 Pages: 21 - 21
Tofacitinib cost effective for moderate-to-severe RA in China Clinical study 01 May 2021 Pages: 23 - 23
Trastuzumab emtansine as second-line therapy for HER2-positive breast cancer: improved survival at high cost Clinical study 01 May 2021 Pages: 24 - 24
Understanding use of bevacizumab for newly diagnosed ovarian cancer in the US before FDA approval Clinical study 01 May 2021 Pages: 25 - 25
Universal varicella vaccination cost effective in Switzerland Clinical study 01 May 2021 Pages: 26 - 26
Use of multiple-frequency bioimpedance device cost effective to guide fluid management for dialysis patients Clinical study 01 May 2021 Pages: 27 - 27
Vericiguat has minimal budget impact as add-on therapy for heart failure Clinical study 01 May 2021 Pages: 28 - 28
Final report and recommendations for lupus nephritis released by ICER News item 01 May 2021 Pages: 29 - 29
ICER white paper explores policy options to improve accelerated approval pathway News item 01 May 2021 Pages: 31 - 31
New NICE strategy aims to provide quicker access to new healthcare Unknown 01 May 2021 Pages: 32 - 32
NICE: draft guidance recommends ravulizumab for rare blood disorder News item 01 May 2021 Pages: 35 - 35
Value assessment of treatments for hereditary angioedema to be updated by ICER Media release 01 May 2021 Pages: 37 - 37